In the 94th Annual Meeting of the Japanese Pharmacological Society, we reported two kinds of pulmonary inflammatory models using lipopolysaccharide (LPS), LPS inhalation model and 𝜶-GalCer-LPS instillation model.
In the previous report, we concluded that these LPS-induced ARI models could be useful to evaluate therapeutic efficacy of drugs used for treatment of pneumonia.
In the present study we carried out further research on LPS instillation model with a pretreatment of α-garactosyl ceramid (α-GalCer), and we also examined the effect of exosome from human adipose cell.
We evaluated inflammatory cell infiltration in BALF (Broncho Alveolar Lavage Fluid), BALF supernatant cytokine level and SpO2.
Exosome was found to be slightly effective to improve symptomatic parameters in this model. The action of exosome changed along with the time of administration. Exosome administrated 4hr after LPS instillation decreased body weight loss, inflammatory cell infiltration, IL-6 and IL-10 levels. On the other hand, administration of exosome 24hr after LPS instillation showed advanced histopathological appearance image of the lung.
The results indicate that characteristic pathophysiological change of this model was identified.